Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CRISPR 2.0: a new wave of gene editors heads for clinical trials

Landmark approval of the first CRISPR therapy paves the way for treatments based on more efficient and more precise genome editors.
  1. Heidi Ledford
    View author publications

    You can also search for this author in PubMed  Google Scholar

Update: On 8 December, the US Food and Drug Administration approved the CRISPR–Cas 9 therapy for sickle cell disease described in this story.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 624, 234-235 (2023)

doi: https://doi.org/10.1038/d41586-023-03797-7

Updates & Corrections

  • Correction 18 December 2023: An earlier version of this article incorrectly stated the location of the Laboratory of Respiratory Diseases and Thoracic Surgery at the Catholic University of Leuven.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links